Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2–Keap1 signaling

• Published in: Pulmonary pharmacology & therapeutics Vol. 22; no. 3; pp. 221 - 236
• Main Authors: Sriram, Narayanan, Kalayarasan, Srinivasan, Sudhandiran, Ganapasam
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2009
• Subjects: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants - metabolism; Antioxidants - pharmacology; Bleomycin; Blotting, Western; Bronchoalveolar Lavage Fluid - cytology; Catechin - analogs & derivatives; Catechin - pharmacology; Collagen - metabolism; EGCG; Fluorescent Antibody Technique; Immunohistochemistry; Inflammation; Interleukin-1beta - metabolism; Intracellular Signaling Peptides and Proteins; Keap1; Kelch-Like ECH-Associated Protein 1; Lung - pathology; Male; Mast Cells - drug effects; Medical Education; Microscopy, Confocal; Nrf2; Proteins - physiology; Pulmonary fibrosis; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - drug therapy; Pulmonary Fibrosis - pathology; Pulmonary/Respiratory; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction - drug effects; Keap1; Inflammation; Bleomycin; Pulmonary fibrosis; Nrf2; EGCG

Abstract The mechanism involved in the enhancement of antioxidant activities and resolved inflammation after epigallocatechin-3-gallate (EGCG) treatment during bleomycin-induced pulmonary fibrosis is investigated in this study. The levels of reactive-oxygen species (ROS), lipid peroxidation (LPO), h...